Pharmaceutical drug developer Acrux could release the results of a phase III clinical trial of its menopause drug as early as Monday. Acrux shares were placed in a trading halt yesterday after the company revealed it had information that would probably have a material effect on the value of its securities -- but which it could not announce immediately. The Age (http://www.theage.com.au/news/business/acrux-shares-in-pause-over-menopause-drug-trial/2006/05/05/1146335926560.html)